MSH2 and Leigh syndrome: In LS, particularly among individuals with MLH1, MSH2, or EPCAM mutations, close monitoring for MM, BCC, SCC, and precancerous lesions—beyond rare sebaceous manifestations—may be warranted starting at age 18.